Exchange: NASDAQ·Updated 07:30 PM EDT

SUPN News

News
all
press releases
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +89.80% and +1.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Supernus Pharmaceuticals Q3 2026 Earnings Call Transcript
Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you byread more...
Benzinga
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
Zacks
Biogen Q3 Preview: Will Growth Products Drive an Earnings Beat?
Biogen heads into Q3 earnings with growth from new drugs and acquisitions potentially offsetting declining multiple sclerosis sales.
Zacks
Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
BIIB's growth products now outpace its legacy MS portfolio, with Skyclarys, Zurzuvae and newer drugs driving a shift in revenue mix.
Zacks
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?
Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders? Are ITGR, BZH, SUPN Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 25, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may...
PR Newswire
SUPN Stock Alert: Halper Sadeh LLC is Investigating Whether Supernus Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) to Indivior Pharmaceuticals, Inc. for 1.5401 common shares of Indivior for each share of Supernus.Halper Sadeh encourages Supernus shareholders to click here to learn more about...
Business Wire
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
Zacks
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026
INDV's proposed Supernus merger could broaden its CNS portfolio, cut costs and reduce reliance on Sublocade, but closing remains uncertain.
Zacks

Advertisement|Remove ads.